Background. Lipoxins are lipoxygenase-derived eicosanoids with anti-inflammatory and proresolution bioactivities in vitro and in vivo. We have previously demonstrated that the stable synthetic LXA 4 analog 15-epi-16-(FPhO)-LXA4-Me is renoprotective in murine renal ischemia/reperfusion injury, as gauged by lower serum creatinine, attenuated leukocyte infiltration, and reduced morphologic tubule injury.
(e.g., aquaporin-1) and the zinc metalloendopeptidase meprin-1␤ implicated in renal remodeling.
Conclusion. Treatment with the lipoxin analog 15-epi-16-(FPhO)-LXA4-Me prior to injury modified the expression of many differentially expressed pathogenic mediators, including cytokines, growth factors, adhesion molecules, and proteases, suggesting a renoprotective action at the core of the pathophysiology of acute renal failure (ARF). Importantly, this lipoxinmodulated transcriptomic response included many genes expressed by renal parenchymal cells and was not merely a reflection of a reduced renal mRNA load resulting from attenuated leukocyte recruitment. The data presented herein suggest a framework for understanding drivers of kidney injury in ischemia/ reperfusion and the molecular basis for renoprotection by lipoxins in this setting.
Ischemic acute renal failure (ARF) remains a formidable clinical problem that is associated with high morbidity and mortality [1, 2] . The pathophysiology of ARF is complex and multipronged and includes persistent intrarenal vasoconstriction, hypoxic injury to microvascular endothelial cells and tubule epithelial cells, and leukocyte-mediated cytotoxicity [1] [2] [3] . Despite the impressive efficacy of agents that target these events in experimental models, none has proved as effective as monotherapy in randomized, controlled clinical trials [1, 2] . Accordingly, attention has shifted toward therapeutic interventions that simultaneously target two or more of the aforementioned pathophysiologic events.
Lipoxins are lipoxygenase-derived arachidonate metabolites that are formed predominantly through cellcell interactions in many human and experimental inflammatory, hypersensitivity, and vascular diseases [4, 6] . The spectrum of bioactivities reported for lipoxins in vitro and in vivo suggests that these lipid mediators may be protective in renal ischemia/reperfusion injury. Lipoxins are potent intrarenal vasodilators that inhibit polymorphonuclear cells (PMNs) chemotaxis, adhesion and migration across the endothelium and epithelium, promote clearance of apoptotic PMNs, and modulate several cytokine responses [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Cyclooxygenase-2 (COX-2), when acetylated by aspirin, catalyzes the generation of 15R-HETE from arachadonic acid [4] . 15R-HETE is then converted by leukocytes to 15R epimers of lipoxins [aspirin-triggered lipoxins (ATLs)] during cell interactions [3] . ATLs share many of the anti-inflammatory and proresolution properties of native lipoxins in vitro [4] . Analogs of LXA 4 and LXB 4 (the major mammalian lipoxin) and of ATLs have been synthesized that are relatively resistant to degradation [4] .
Importantly, they display many of the biologic properties of native lipoxins and ATLs in vitro and are potential prototype therapeutics [14] . Native LXA 4 , ATLs, and several synthetic lipoxin analogs have already been demonstrated to have impressive anti-inflammatory and proresolution activity in experimental dermal inflammation, glomerulonephritis, and hind limb-induced second organ injury [15] [16] [17] [18] [19] [20] .
We have previously demonstrated the protective effect of a stable analog of aspirin-triggered 15-epi-LXA 4 , 15epi-16-(FPhO)-LXA 4 -Me in experimental murine ARF in vivo as manifested by significant functional and morphologic protection and by blunted chemokine and cytokine responses [21] . The latter experiments focused on a relatively small number of mediators that have previously been implicated in the pathogenesis of ischemia/ reperfusion injury or have been identified as players in lipoxin-mediated cytoprotection in other systems. While such targeted approaches can shed valuable new light on molecular mechanisms of disease, they are, by definition, biased by and dependent on, previous work in the biologic system of interest or in related systems. With advances in transcriptomics, it is now apparent that even simple perturbations of single-cell systems induce complex and highly coordinated changes in gene expression. By applying these emerging technologies to well-characterized disease models it should be possible to decipher, in an unbiased fashion, the full spectrum of genomic events that underpin organ dysfunction and the complex symphony of interrelationships within these disease-related gene expression networks, ultimately identifying the genomic switches that direct these responses toward resolution and repair. Against this background, we have employed transcriptome profiling using oligonucleotide microarrays and computational gene annotation in the present study to identify the profile of genes whose expression is altered in experimental murine ischemia/ reperfusion injury, and to probe ischemia/reperfusion injury-modulated genes whose expression levels are further influenced by 15-epi-16-(FPhO)-LXA 4 -Me.
METHODS

Experimental ischemia/reperfusion injury
ARF was induced in National Institutes of Health (NIH) Swiss mice (25 to 35 g) by clamping both renal pedicles for 30 minutes, followed by 24 hours of reperfusion [21] . Animals received a 15 g single bolus injection of 15-epi-16-(FPhO)-LXA 4 -Me or an equivalent volume of its vehicle into the inferior vena cava 10 minutes prior to clamping. Sham-operated animals served as controls. The influence of the lipoxin analog on changes in renal function, morphology, and PMN infiltration in these mice has been previously reported [21] . As a second model of ARF, murine folic acid-induced acute tubular necrosis (ATN) was used. This model, as previously described [22] , involved administering 250 mg/kg body weight of folic acid by intraperitoneal injection. Animals were sacrificed at 0, 3, 6, 24, and 72 hours. Serum creatinine increased approximately four-to five-fold over the course of the experiment [22] .
Taqman-PCR
Total RNA was isolated from murine kidneys and spleens using Trizol solution (Gibco, Paisley, UK) according to the manufacturer's instructions. For real-time polymerase chain reaction (PCR) analysis of murine tissue, chromosomal DNA was removed from total RNA using DNase I. DNAse-treated RNA (2 g) was transcribed to cDNA using standard procedures. Real-time PCR was performed on a TaqMan ABI 7700 Sequence Detection System (Applied Biosystems, Weiterstadt, Germany) using heat-activated TaqDNA polymerase (Amplitaq Gold; Applied Biosystems, Weiterstadt, Germany) [23] . After an initial hold of 2 minutes at 50ЊC and 10 minutes at 95ЊC, the samples were cycled 40 times at 95ЊC for 15 seconds and 60ЊC for 60 seconds. Target gene forward and reverse primers and probes were designed using Primer Express 1.5 software (Applied Biosystems, Foster City, CA, USA). Commercially available predeveloped TaqMan assay reagents (PDARs) were used for the internal standards human glycerin-aldehyde-3-phosphate-dehydrogenase (GAPDH) and 18S ribosomal RNA (18S rRNA). All primers and probes were obtained from Applied Biosystems, Weiterstadt, Germany. The primers were cDNA-specific, not amplifying genomic DNA. The following sequence of oligonucleotide primers (300 nmol) and probes (100 nmol) were used: (1) ADAM8 (forward primer: 5Ј-GCCCCTTGA ACGCTCCTT-3Ј; reverse primer: 5Ј-TTCCATCCAT GCAAACCTTTC-3Ј; and probe: 5Ј-TATTGCAGGG CACCAAGTGCGAGG-3Ј); (2) claudin-1 (forward primer: 5Ј-GATGTGGATGGCTGTCATTGG -3Ј; reverse primer: 5Ј-CCATGCTGTGGCCACTAATGT-3Ј; and probe: 5Ј-CGCCAGACCTGAAAT-3Ј); (3) claudin-3 (forward primer: 5Ј-CATCACGGCGCAGATC AC-3Ј; reverse primer: 5Ј-TGCTCTGCACCACGCA GTT-3Ј; and probe: 5Ј-CATCCACAGGCCCTC-3Ј); (4) claudin-7 (forward primer: 5Ј-ATGATGAGCTGCAA AATGTACGA-3Ј; reverse primer: 5Ј-CACCAGGGA CACCACCATTAA-3Ј; and probe: 5Ј-CCCTGCAGGC CACT-3Ј); and (5) meprin-1␤ (forward primer: 5Ј-CAC AAGAGATGGCCACATACCA-3Ј; reverse primer: 5Ј-CGATAGCGCTCAAAAGCATTG-3Ј; and probe: 5Ј-CAGCTTGGAAATGAAT-3Ј).
Target and housekeeper cDNA templates (GAPDH and 18S rRNA) were quantified by standard curves of diluted standard cDNA. The expression of each target gene was normalized to both different housekeeping transcripts. All measurements were performed in duplicate. Controls consisting of ddH 2 O were negative in all runs.
Oligonucleotide microarray (gene chip) analysis
Twelve g of total RNA were annealed to the T7-(dt) 24 primers. First-strand cDNA synthesis was completed by incubating the mixture with 2 L of Superscript II RT (20,000 units) at 42ЊC for 1 hour. Second-strand synthesis was carried out in a total volume of 150 L. Following purification, the cDNA pellet was precipitated with ammonium acetate and resuspended in RNAse-free water. Synthesis of cRNA was performed by in vitro transcription. The amplified cRNA was purified with an affinity resin column. The cRNA was fragmented and hybridized to the Affymetrix GeneChip Murine U74Av2 array (Santa Clara, CA, USA), permitting the assessment of the abundance of approximately 12,500 mRNA transcripts representing known genes and ESTs. Hybridization proceeded overnight. Subsequent washing and staining of the arrays was carried out using the Affymetrix GeneChip fluidics station protocol EukGE-WS2 (Santa Clara, CA, USA). Following washing and staining, the probe arrays were scanned twice at 3 m resolution using the Affymetrix GeneChip System confocal scanner (Santa Clara, CA, USA).
Data analysis was performed using Affymetrix Gene-Chip software (Santa Clara, CA, USA). The criteria used to identify significant differential regulation of the transcripts was a greater than 2.0-fold change in expression in replicate experiments.
Bioinformatic annotation of unknown sequences
cDNA sequences which did not show homology with known genes by Basic Local Alignment Search Tool (BLAST) search against the nonredundant database were used as input into an annotation pipeline. Briefly, the annotation pipeline consisted of serial stages of homology searching, using BLAST and position-specific iteration (PSI)-BLAST searches of the high-throughput genomic sequence databases to identify genomic clones [24, 25] . The identified clones were used in GENSCANbased sequence topography analysis to identify gene fea-tures such as introns, exons, and promoter regions [26] . Having determined the sequence of the gene, the amino acid sequence of corresponding proteins was deduced by open reading frame analysis. The amino acid sequences were thus assembled further by homology searching of the existing protein databases and structural modeling of the protein to identify conserved structural motifs or structural domains shared by other proteins. For protein structural analysis, the structure prediction meta server was employed [27] . This is an integrated platform for the utilization of a number of high-quality structure prediction servers and permits identification of conserved sequences by comparison with the Structural Classification of Proteins (SCOP) database [28] .
RESULTS AND DISCUSSION
Oligonucleotide microarrays identify claudin-1, -3, and -7, and ADAM8 among 226 known genes whose mRNA levels are increased in response to experimental murine renal ischemia/reperfusion injury To reduce the impact of background physiologic interanimal variation on mRNA levels, total RNA was pooled from three individual animals from sham-operated and ischemia/reperfusion injury animal groups. Oligonucleotide microarray analyses were performed in duplicate with a correlation coefficient between experiments of 0.92. Of a total of 12,488 genes displayed on the microarray, 6795 (54%) were expressed in the kidney under basal conditions. Of these, 1016 were altered following ischemia/reperfusion injury, 445 of which had expression changes of two-fold or greater. Two hundred twenty-six known genes were found to be up-regulated. Table 1 shows changes in several functional classes of genes implicated in the pathogenesis of ischemic ARF that are candidate targets for lipoxin-mediated renoprotection, including chemoattractants, cytokines, chemokines and chemokine receptors (e.g., interleukin-6, GRO-1, interferon-␥, and C-C receptor 1); growth factors and related molecules (e.g., thrombospondin-1 and early growth response gene 1); adhesion molecules (e.g., intercellular adhesion molecule-1); cell cycle and apoptosis-related genes (e.g., 14-3-3-and annexin III); transcription factors (e.g., ATFx); proteases (e.g., lipocalin-2); and cytoskeletal proteins (e.g., ␤-tubulin).
Among the molecules previously implicated in the pathogenesis of ischemic ARF whose mRNA levels were increased with microarray analysis are the adhesion molecules ICAM-1 and vascular cellular adhesion molecule-1 (VCAM-1), the cell cycle inhibitors p21 and 14-3-3-sigma, and an EST homologous to rat kidney inducible molecule-1 (KIM-1) [29] [30] [31] . These served as positive controls for the system. Of interest was the coordinated up-regulation of three members of the claudin family, claudins 1, 3, and 7. Claudins are tight junction integral Abbreviations are: IFN-␤, interferon beta; IL-1, interleukin-1; TNF, tumor necrosis factor; ICAM-1, intercellular adhesion molecule-1; VCAM-1, vascular cellular adhesion molecule-1; CPETR2, clostridium perfringens enterotoxin receptor 2; KIM-1, kidney inducible molecule-1; SSeCKS, SrC-suppressed C kinase substrate; ATFx, expression of a specific mouse gene; ADAM8, a disintegrin and metalloproteinase domain protein 8.
a Oligonucleotide microarrays (OM) analyzed RNA pooled from 3 sham and 3 ischemia/reperfusion injury animals, fold change reflecting expression in ischemia/ reperfusion injury animals using sham as baseline for comparison
Fig. 1. Confirmation by real-time polymerase chain reaction (RT-PCR) of differential expression of oligonucleotide microarray-identified genes in experimental ischemia/reperfusion injury in murine kidneys in vivo and modification of expression by 15-epi-16-(FPhO)-LXA 4 -Me.
RT-PCR confirms up-regulation of claudin-1, claudin-3, claudin-7, and ADAM8, and down-regulation of meprin-1␤ in murine kidneys harvested from mice with experimental ischemia/reperfusion injury ( ) as compared to sham-operated controls () and modification of expression by 15-epi-16-(FPhO)-LXA 4 -Me (ᮀ). Expression data is shown as ratio to 18SrRNA (y axis shows ratio to rRNA). membrane proteins [32] . To date, 24 members of the claudin gene family have been described [32] . Within the kidney, claudins form an important part of tight junctions, as vividly highlighted with the reporting that mutations in claudin-16 (paracellin-1), which is exclusively expressed in the thick ascending limb of Henle, are associated with hereditary hypomagnesemia [33] . Damage to tight junctions resulting in impaired cell-cell adhesion and disruption of the permeability barrier are features of epithelial cell damage in ischemic acute renal failure [34] .
To confirm the differential expression of these key modulators of barrier integrity, real-time PCR was performed with RNA extracted from the kidneys of animals with ischemia/reperfusion injury ( Fig. 1 ). Under basal conditions mouse kidneys expressed little mRNA for claudin-1, whereas mRNA levels were significantly enhanced following ischemia/reperfusion injury. Similarly, low expression of claudin-3 was seen in sham-operated animals, whereas claudin-3 mRNA levels were significantly enhanced in ischemia/reperfusion injury. Claudin-7 expression was also induced in the latter setting. Real-time PCR demonstrated fold increases of 6.97, 4.71, and 9.24 for claudin-1, -3, and -7, respectively, confirming the data obtained with oligonucleotide microarrays. Messenger RNA levels for several other claudins (claudin-8 and -6) and tight junction proteins (occludin and junctional adhesion molecule) expressed by the kidney were not perturbed during ischemia/reperfusion injury (data not shown), while mRNA for claudin-2 was suppressed [Ϫ1.9-fold on both oligonucleotide microarrays (OM), not reaching cutoff levels used for this analysis], suggesting differential regulation of gene expression in this setting. The finding of higher mRNA levels for claudin-1, -3, -7 in the context of ischemia/reperfusion injury is intriguing given the dramatic changes in epithelial polarity and adhesion that typifies ischemic ATN [3] . Indeed, recent studies have suggested additional dynamic roles for claudins as modulators of cell signaling and the actin cytoskeleton [32] . Claudin proteins, including claudin-1 perturbed during ischemia/reperfusion injury in the present study, have been shown to recruit membrane-type matrix metalloproteinases (MT-MMPs), including promatrix metalloproteinase-2, enhancing activation of pro-MMP-2 in vitro [35] . Together these observations raise the possibility of a role for claudins in tissue remodeling in ischemic ARF.
In light of the perturbations in claudin expression described above and their potential role in regeneration and repair, it is noteworthy that renal mRNA levels for a disintegrin and metalloproteinase domain protein 8 (ADAM8) were also enhanced in experimental IRI. This finding was confirmed by real-time PCR analysis (Fig.  1) . The ADAM gene family is composed of proteins that have transmembrane and cytoplasmic domains composed of MMP-like, disintegrin-like, cysteine-rich, and epidermal growth factor (EGF)-like (snake venom MMP-like) domains. ADAM family members have been implicated in cell fusion, cell-to-matrix adhesion, and proteolytic degradation of extracellular matrix, [36] and can modulate cell signaling systems which are key for normal cellular processes such as cell morphogenesis, wound healing, and tumor cell invasion [37] .
Changes in renal mRNA levels following ischemia/ reperfusion injury could represent ischemia/reperfusion injury-triggered changes in the renal parenchymal transcriptome, infiltration of renal parenchyma by leukocytes, or a combination of these events. In this regard, it is noteworthy that neither claudin-1 nor ADAM8 were expressed in splenic tissue harvested from sham-operated and ischemia/reperfusion injury animals, as assessed by RT-PCR, suggesting that the increase in their renal mRNA levels in ischemia/reperfusion injury reflected perturbation of the transcriptome of resident renal cells.
Oligonucleotide microarrays identify epidermal growth factor and meprin-1␤ among 112 known genes whose mRNA levels are decreased in response to experimental ischemia/reperfusion injury Of the 445 transcripts (25%) whose mRNA levels were altered two-fold or greater in experimental ischemia/ reperfusion injury, 112 were down-regulated. Among the a Oligonucleotide microarrays (OM) were performed with RNA pooled from 3 sham and 3 ischemia/reperfusion injury animals, fold change reflecting expression in ischemia/reperfusion injury using sham as baseline for comparison major families of genes whose mRNA levels were suppressed were chemoattractants, cytokines, chemokines and chemokine receptors (e.g., stromal cell derived factor-1 and leukemia inhibitory factor receptor; growth factors [e.g., EGF, angiogenin, and fibroblast growth factor]; adhesion molecules (e.g., mitsugumin 29); cell cycleand apoptosis-related genes (e.g., glutathione-S-transferase 1); proteases (e.g., meprin-1␤; and cytoskeletal proteins (e.g., adseverin) ( Table 2 ).
In keeping with previous reports, renal expression of EGF was transiently decreased after ischemia/reperfusion injury, further validating the approach [38] . A noteworthy finding was down-regulation of meprin-1␤ (meprin B). Suppression of meprin-1␤ was confirmed by real-time PCR analysis of RNA from the kidneys of sham-operated and ischemia/reperfusion injury animals ( Fig. 1) . Normal mouse kidney displays strong detectable meprin transcript levels, the expression of which is blunted in the injured kidney. Meprins (A and B) are zinc metalloendo-peptidases expressed by renal proximal tubules and brush border membranes of the intestine [39] . Meprin A is composed of homodimers of ␣ subunits, whereas meprin B is a heterodimer of ␣ and ␤ subunits. Meprins ␣ and ␤ subunits have markedly different substrate and peptide bond specificity, meprin ␣ preferring substrates with small or hydrophobic residues while meprin ␤ selects for acidic amino acids, such as those found in the peptide hormone gastrin [40] . Meprin A inhibition has been described as protective in ischemia/reperfusion injury [41] , while little is known about meprin B in ischemia/reperfusion injury. Meprins are the only known endopeptidases in brush border membranes that degrade proteins. Interestingly, down-regulation of meprin-1␤ has been recently reported in experimental hydronephrosis, suggesting that diverse renal insults modulate the expression of this endopeptidase in vivo [42] .
Real-time PCR analysis of mRNA levels in mice with folic acid-induced ATN also demonstrated increased levels for claudin-1, -3, and -7, and ADAM8, and decreased meprin-1␤ mRNA levels, suggesting that these events are common to both ischemic and nephrotoxic ATN (Fig. 2) .
Bioinformatic annotation of cDNAs corresponding to transcripts without homology to known genes identifies a further cohort of genes whose expression is altered in experimental ischemia/reperfusion injury
Of the 445 renal transcripts altered in response to ischemia/reperfusion injury, 107 corresponded to ESTs without homology to known genes, as determined by standard database search strategies of the human and murine genome databases. The annotation of these transcripts remains a major obstacle to the streamlined analysis of data derived from commercial microarrays. To further characterize these transcripts we employed a computational gene annotation pipeline as described in the experimental procedures. These studies have led to the identification of a further 24 genes whose expression is altered in response to renal ischemia/reperfusion injury, a representative cohort of which are detailed in Table 3 . The unknown sequences identified in the microarray experiment were used as input to the annotation pipeline. Typical of such analysis was the EST AI836034, found to be up-regulated 2.1-and 2.3-fold on oligonucleotide microarrays 1 and 2, respectively. First, the sequence was retrieved using the ENTREZ sequence retrieval system at the National Centre for Biotechnology Information. This EST, UI-M-AQ0-aad-f-06-0-UI.s2, when compared to the nonredundant nucleotide databases this sequence produced no significant homology to any known gene. However this sequence was 99% identical to a 998-nucleotide cDNA clone from adult mouse brain, clone:0710007K04. To determine the genomic structure of this sequence, GENSCAN analysis of the clone topography was completed. This algorithm identifies features such as introns, exons, and promoter regions in genomic sequence. Analysis of cDNA clone:0710007K04 demonstrated the presence of a 218 amino acid single exon protein. The EST sequence used as input was contained within the predicted open-reading frame of the cDNA, positioned in the 5Ј untranslated region adjacent to the amino acid sequence. Pairwise alignment was performed with the EST and cDNA sequences to confirm the predicted location. The amino acid sequence thus generated was then compared to the nonredundant protein database, where a substantial homology was found to a human protein similar to enigma (LIM domain protein) (GenBank accession no. AAH14521). Enigma proteins are a family of cytoplasmic proteins that possess a PDZ domain at the amino terminal and one to three Lun-11 Isle-1 mec-3 (LIM) domains at the carboxyl terminal. By virtue of these two protein interacting domains, enigma proteins are capable of protein-protein interactions. It has been proposed that enigma proteins may act as adapters between kinases and the cytoskeleton [43] . This general approach was used to identify 10 up-regulated and 14 down-regulated genes in experimental renal ischemia/reperfusion injury.
Modulation of the renal transcriptomic response to ischemia/reperfusion injury by 15-epi-16-(FPhO)-LXA 4 -Me
We have previously demonstrated a protective effect of a lipoxin-stable analog 15-epi-16-(FPhO)-LXA 4 -Me in renal ischemia/reperfusion injury, establishing the therapeutic potential of lipoxin and ATL analogs in this setting (Fig. 3) [21] . The renoprotective effect of 15-epi-16-(FPhO)-LXA4-Me was associated with reduced PMN infiltration and modulated intrarenal cytokine expression. The finding of reduced mRNA levels for interleukin-1 (IL-1), IL-6 and GRO-1 in lipoxin-treated animals in association with increased expression of suppressors of cytokine signaling (SOCS) -1 and SOCS-2 suggests that a complex interplay of transcriptional events underpin the renoprotective effect of lipoxin in experimental ischemia/reperfusion injury [21] . To further define the molecular events associated with renoprotection we performed oligonucleotide microarray-based comparison of mRNA expression profiles in the ischemia/reper-fusion injury kidneys in the presence and absence of 15-epi-16-(FPhO)-LXA4-Me. For the purposes of this analysis, ischemia/reperfusion injury-associated gene expression levels served as basal levels and lipoxin-mediated changes were expressed as fold change relative to this baseline parameter. Pretreatment with lipoxin analog resulted in a blunting of ischemia/reperfusion injuryassociated gene induction (Tables 4 and 5) . This effect was observed in all of the functional classes of genes induced by ischemia/reperfusion injury, including inflammatory mediators such as chemoattractants, cytokines, chemokines and chemokine receptors, growth factors, adhesion molecules, and other genes. This marked attenuation in both the magnitude and spectrum of gene expression changes applied to genes typically expressed by infiltrating leukocytes (e.g., CD14 and lipocortin 1) and to genes whose expression is most abundant in resident epithelial cells (e.g., claudins, KIM-1).
In addition to attenuating proinflammatory responses induced by a range of important mediators, lipoxins, ATLs, and their analogs actively promote resolution of inflammation by promoting macrophage clearance of apoptotic neutrophils and by stimulating the release of cytokines and growth factors implicated in tissue remodeling and repair [e.g., transforming growth factor (TGF) beta] [3, 4] .
In a second analysis we investigated whether lipoxin treatment was associated with modulation of the expres- Ϫ2.0
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For abbreviations, see Table 1 . a Oligonucleotide microarrays (OM) analyzed RNA pooled from 3 sham and 3 ischemia/reperfusion injury animals b Fold change reflecting expression in ischemia/reperfusion injury animals using sham as baseline for comparison c Fold change reflecting expression in lipoxin-treated using ischemia/reperfusion injury as baseline for comparison sion of a cluster of genes that was not perturbed by ischemia/reperfusion injury alone and could represent a lipoxin-stimulated renoprotective genomic program. To this end, 5779 of the total number of 6795 renalexpressed genes displayed on the microarray (80%) were not perturbed by ischemia/reperfusion injury alone. Of these, 7 known genes (0.12%) were perturbed by twofold or more during lipoxin treatment on both microarrays, 6 genes being induced and 1 gene being suppressed ( Table 6 ). The relatively small number of lipoxin-responsive, ischemia/reperfusion injury-independent genes identified in this analysis, in comparison to the striking modulation of ischemia/reperfusion injury-associated genes, suggests that the lipoxin analog conferred renoprotection either by inhibiting a pathogenic event, yet to be defined at the core of ischemia/reperfusion injury, or that the analog had dramatic effects on gene expression by virtue of its ability to influence several key pathophysiologic events in parallel, such as vascular tone, leukocyte recruitment and clearance, and cytokine responses. Most lipoxinmediated effects reported to date are mediated through engagement of specific G protein-coupled lipoxin receptors [5] . LXA 4 also modulates activation and transactivation of growth factor receptors [13] . Our data do not exclude a role for these events at different time points throughout the course of ischemia/reperfusion injury. It was striking in the present study that the lipoxin analog prevented ischemia/reperfusion injury-induced changes in mRNA levels for most genes and was not limited to a specific family or families of genes. This observation suggests that the lipoxin analog modulated a single pathophysiologic event at the core of ATN and related downstream processes or modulated a number of important events in parallel. The latter would appear most likely, given the compelling evidence from in vitro systems that lipoxin can influence a variety of pathobiologic functions that are relevant to ischemic ATN, including vascular tone, epithelial cell injury, cytokine release, and leukocyte recruitment and clearance (vide supra).
CONCLUSION
The ischemia/reperfusion injury-associated and renoprotective transcriptomic changes described herein will provide the template for further dissection of the molecular component of renal injury by ischemia/reperfusion injury and other insults in vitro and for the elucidation of novel mechanisms of renoprotection in renal disease.
